Net revenue increased to $28.2 million for Q2 2022; Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS® (voclosporin) for 2022 Continued increases in LUPKYNIS Patients on Treatment; Steady Conversion Rates and Payor Coverage EMA review of LUPKYNIS remains on track with decision expected by the end of Q3 2022 $391.7 million … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “North America Idiopathic Pulmonary Fibrosis Market Size, Share & Industry Trends Analysis Report By Drug Type, By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Providers, By Country and Growth Forecast, 2021-2027” report has been added to ResearchAndMarkets.com’s offering. The North America Idiopathic Pulmonary Fibrosis Market is expected to witness market growth of … [Read more…]
LONDON–(BUSINESS WIRE)–AIBODY, the world’s first Physiology-as-a-Service platform, announced today that it has signed a collaboration agreement with the German Heart Centre Berlin (DHZB), a leading medical research institute specializing in cardiovascular disease. This agreement focuses on the development of a suite of innovative solutions that will facilitate the diagnosis and treatment of congenital heart disease. … [Read more…]
Approval marks the first all-oral, once-daily, fixed-duration Bruton’s tyrosine kinase (BTK) inhibitor-based regimen for first-line treatment of CLL BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission granted marketing authorisation for the expanded use of IMBRUVICA® (ibrutinib) in an all-oral, fixed-duration (FD) treatment combination with venetoclax (I+V) for … [Read more…]
CAMBRIDGE, England–(BUSINESS WIRE)–#lifechanginganswers–Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has selected the GenomOncology Precision Oncology Platform for the development of a novel ground-breaking CE-IVD Precision Oncology Solution. Driven by the increasing adoption of cancer genomics and the growing need to individualize therapeutic recommendations, Congenica is developing … [Read more…]
BOSTON–(BUSINESS WIRE)–PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) plans to announce its half-yearly results for the six months ended June 30, 2022, on Thursday, August 25, 2022. A presentation and conference call for analysts and shareholders will take place at 9:00am EDT / 2:00pm BST on the day of publication, and … [Read more…]
Labs can now launch next-gen testing in days versus months and improve patient experience and outcomes SAN FRANCISCO–(BUSINESS WIRE)–1health.io Inc. (“1health”), an industry-leading healthcare tech company that empowers laboratories to make diagnostic testing accessible and affordable at scale, announces the launch of its Next Generation Diagnostic Platform. With 1health’s innovative platform, laboratories can expand market … [Read more…]
AHF Zoom Press Telecon: Thurs., August 4 @ 11:00 am PT Now that both the State of California and Los Angeles County have declared states of emergency on monkeypox, AHF is urging L.A. County health officials to swiftly ramp up and improve its uneven response to the virus outbreak that is primarily affecting gay men … [Read more…]
DIC leverages world-class algae cultivation tech, expanding health, personal care offerings TOKYO–(BUSINESS WIRE)–#Biotech—DIC Corporation (TOKYO:4631) and biotech startup Green Science Materials, Inc. (GSM) expand their collaboration on Suizenji Nori blue-green algae and SACRANTM polysaccharide extract, developing Suizenji Nori indoor mass cultivation technology needed to deliver the stable production of SACRANTM required for global scale. This … [Read more…]
Financial Highlights Second Quarter 2022: Revenue of $246.2 million, an increase of 16% from second quarter 2021 GAAP net loss of $490.0 million, which includes a $519.9 million loss on impairment related to our decision to exit the Episodes of Care Services segment. Non-GAAP adjusted EBITDA1 of $62.6 million, an increase of 15% from second … [Read more…]
